In ovarian cancer, activating mutations in oncogenes such as KRAS, BRAF and PIK3CA are common in low-grade (type I) ovarian tumors, while TP53 mutations are frequent in high-grade (type II) ovarian tumors [3]. This evidence concerns the gene TP53 and ovarian cancer.